Inspire(US:INSP) Businesswireยท2025-11-13 21:39Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for securities fraud, following a significant drop in stock price due to poor performance and misleading statements regarding the launch of its new sleep apnea device, Inspire V [1][4][5]. Company Performance - On August 4, 2025, Inspire disclosed that the launch of the Inspire V device was facing delays due to issues such as incomplete training for treatment centers, software update delays, and excess inventory leading to poor demand [3]. - The company reduced its 2025 earnings guidance by over 80%, from a range of $2.20 to $2.30 per share down to $0.40 to $0.50 per share [3]. Stock Market Reaction - Following the announcement on August 5, 2025, Inspire's stock price fell by $42.04, or 32.4%, closing at $87.91 per share, which resulted in significant losses for investors [4]. Allegations in the Lawsuit - The lawsuit alleges that during the class period, the company made materially false and misleading statements and failed to disclose adverse facts about its business and operations, including poor demand for Inspire V and issues with training and IT systems [5]. - Specific failures included not completing necessary training for treatment centers, not updating critical software for claims processing, and not ensuring Medicare reimbursement was in place at launch [5].